JP2009517347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517347A5 JP2009517347A5 JP2008541602A JP2008541602A JP2009517347A5 JP 2009517347 A5 JP2009517347 A5 JP 2009517347A5 JP 2008541602 A JP2008541602 A JP 2008541602A JP 2008541602 A JP2008541602 A JP 2008541602A JP 2009517347 A5 JP2009517347 A5 JP 2009517347A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- anticancer agent
- parapoxvirus ovis
- parapoxvirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700639 Parapoxvirus Species 0.000 claims 6
- 241000283898 Ovis Species 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
Claims (7)
- 癌の処置用の医薬を製造するための、少なくとも１種のさらなる抗癌剤と組み合わせたパラポックスウイルスオヴィスの使用であって、抗癌剤が細胞傷害性物質である、使用。
- 少なくとも１種のさらなる抗癌剤と組み合わせて癌を処置するための医薬を製造するための、パラポックスウイルスオヴィスの使用であって、抗癌剤が細胞傷害性物質である、使用。
- 癌が、黒色腫、乳癌、前立腺癌、肺癌、結腸直腸癌、肝臓癌、膀胱癌、内分泌系の癌、神経系の癌、リンパ腫またはこれらの各々の原発性癌の転移性疾患である、請求項１および請求項２のいずれかに記載の使用。
- パラポックスウイルスオヴィスが、パラポックスウイルスオヴィス株Ｄ１７０１、ＮＺ−２、ＮＺ−７、ＮＺ−１０もしくはｏｒｆ−１１、または、これらの株の植え継ぎにより得られるパラポックスウイルスである、請求項１ないし請求項３のいずれかに記載の使用。
- パラポックスウイルスオヴィスが不活性化形態で存在する、請求項１ないし請求項４のいずれかに記載の使用。
- 医薬が腫瘍の大きさまたは腫瘍の質量の低減をもたらす、請求項１ないし請求項５のいずれかに記載の使用。
- 抗癌剤が、ビンブラスチン、ビンクリスチン、ドセタキセル、パクリタキセルからなる群から選択される、請求項１ないし請求項６のいずれかに記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05025600 | 2005-11-24 | ||
| EP05025600.7 | 2005-11-24 | ||
| PCT/EP2006/009855 WO2007059821A1 (en) | 2005-11-24 | 2006-10-12 | Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009517347A JP2009517347A (ja) | 2009-04-30 |
| JP2009517347A5 true JP2009517347A5 (ja) | 2009-08-27 |
| JP5164849B2 JP5164849B2 (ja) | 2013-03-21 |
Family
ID=37654955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541602A Active JP5164849B2 (ja) | 2005-11-24 | 2006-10-12 | 癌の処置用の生物化学療法としての古典的細胞傷害性化学療法剤と組み合わせたパラポックスウイルス |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7897159B2 (ja) |
| EP (1) | EP1951274B1 (ja) |
| JP (1) | JP5164849B2 (ja) |
| CN (1) | CN101312737B (ja) |
| AR (1) | AR057922A1 (ja) |
| AT (1) | ATE450266T1 (ja) |
| CA (1) | CA2630833C (ja) |
| DE (1) | DE602006010902D1 (ja) |
| DK (1) | DK1951274T3 (ja) |
| ES (1) | ES2335308T3 (ja) |
| HK (1) | HK1117427A1 (ja) |
| PL (1) | PL1951274T3 (ja) |
| PT (1) | PT1951274E (ja) |
| TW (1) | TWI415617B (ja) |
| WO (1) | WO2007059821A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
| EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3816139A1 (de) | 1987-10-17 | 1989-04-27 | Bayer Ag | Verfahren zur herstellung von paramunitaetsinducern |
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| PL366397A1 (en) * | 2000-07-11 | 2005-01-24 | Bayer Aktiengesellschaft | Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| AR035227A1 (es) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| NZ512341A (en) * | 2001-06-13 | 2004-02-27 | Bayer Ag | Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments |
| KR101170653B1 (ko) * | 2002-08-12 | 2012-08-03 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
-
2006
- 2006-10-12 WO PCT/EP2006/009855 patent/WO2007059821A1/en active Application Filing
- 2006-10-12 DK DK06806214.0T patent/DK1951274T3/da active
- 2006-10-12 EP EP06806214A patent/EP1951274B1/en active Active
- 2006-10-12 ES ES06806214T patent/ES2335308T3/es active Active
- 2006-10-12 DE DE602006010902T patent/DE602006010902D1/de active Active
- 2006-10-12 PL PL06806214T patent/PL1951274T3/pl unknown
- 2006-10-12 AT AT06806214T patent/ATE450266T1/de active
- 2006-10-12 CA CA2630833A patent/CA2630833C/en active Active
- 2006-10-12 PT PT06806214T patent/PT1951274E/pt unknown
- 2006-10-12 CN CN2006800439506A patent/CN101312737B/zh active Active
- 2006-10-12 JP JP2008541602A patent/JP5164849B2/ja active Active
- 2006-11-23 TW TW095143295A patent/TWI415617B/zh active
- 2006-11-23 AR ARP060105172A patent/AR057922A1/es not_active Application Discontinuation
-
2008
- 2008-05-19 US US12/123,360 patent/US7897159B2/en active Active
- 2008-11-10 HK HK08112329.9A patent/HK1117427A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009517347A5 (ja) | ||
| MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
| EP2322650A8 (en) | MicroRNAs and uses thereof | |
| MX2010000465A (es) | Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores. | |
| NZ598588A (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
| MX2010003564A (es) | Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso. | |
| MY188911A (en) | Methods of treating bladder cancer | |
| WO2012009406A3 (en) | Gold particles and methods of making and using the same in cancer treatment | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| TW201611831A (en) | Novel antitumoral use of CABAZITAXEL | |
| JP2013501791A5 (ja) | ||
| EP2322662A8 (en) | MicroRNAs and uses thereof | |
| WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
| MX336761B (es) | Compuestos para el tratamiento de cancer. | |
| JP2013544892A5 (ja) | ||
| MX2011004979A (es) | N-cadherina:blanco para diagnosis y terapia de cancer. | |
| WO2011109422A3 (en) | Compositions and methods for the treatment of cancer | |
| JP2018510631A5 (ja) | ||
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| TW200738250A (en) | Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| WO2020231997A9 (en) | Non-coding rna for subtyping of bladder cancer | |
| NZ598131A (en) | Anti-angiogenesis therapy for the treatment of previously treated breast cancer | |
| MX2010009697A (es) | Tratamientos anticancerigenos mejorados. |